Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 134,986 251,929 319,053 656,089
Total Sell Value $11,097,511 $21,508,551 $27,661,182 $61,420,002
Total People Sold 5 6 7 7
Total Sell Transactions 9 19 27 56
End Date 2024-04-07 2024-01-05 2023-07-07 2022-07-07

   
Records found: 1285
  Page 46 of 52  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Heron Elaine J Director   –       •      –    2015-06-10 4 A $0.00 $0 D/D 1,100 20,625     -
   Bate Kenneth Director   –       •      –    2015-06-10 4 A $0.00 $0 D/D 1,100 11,875     -
   Baffi Robert EVP, Technical Operations   •       –      –    2015-06-09 5 GA $0.00 $0 I/I 2,500 31,676     -
   Baffi Robert EVP, Technical Operations   •       –      –    2015-06-09 5 GD $0.00 $0 D/D 2,500 97,000     -
   Davis George Eric SVP, General Counsel   •       –      –    2015-06-08 4 GD $0.00 $0 D/D 120 67,618     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2015-06-05 4 AS $122.30 $201,669 D/D (1,649) 28,229     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2015-06-05 4 AS $122.32 $228,001 D/D (1,864) 72,846     -
   Baffi Robert EVP, Technical Operations   •       –      –    2015-06-05 4 GA $0.00 $0 I/I 1,506 29,176     -
   Baffi Robert EVP, Technical Operations   •       –      –    2015-06-05 4 GD $0.00 $0 D/D 1,506 99,500     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2015-06-04 4 D $120.46 $216,948 D/D (1,801) 29,878     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2015-06-04 4 D $120.46 $245,257 D/D (2,036) 74,710     -
   Mueller Brian VP, Corporate Controller   •       –      –    2015-06-04 4 D $120.46 $62,880 D/D (522) 11,926     -
   Davis George Eric SVP, General Counsel   •       –      –    2015-06-04 4 D $120.46 $179,244 D/D (1,488) 67,738     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-06-04 4 D $120.46 $799,854 D/D (6,640) 229,254     -
   Baffi Robert EVP, Technical Operations   •       –      –    2015-06-04 4 D $120.46 $198,036 D/D (1,644) 101,056     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2015-06-04 4 AS $122.35 $166,646 D/D (1,362) 35,605     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2015-06-04 4 D $120.46 $179,244 D/D (1,488) 36,967     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2015-06-01 4 AS $124.16 $489,811 D/D (3,945) 31,679     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2015-06-01 4 AS $123.76 $46,657 D/D (377) 38,455     -
   Mueller Brian VP, Corporate Controller   •       –      –    2015-05-31 4 D $125.57 $38,676 D/D (308) 12,448     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2015-05-31 4 D $125.57 $51,860 D/D (413) 38,832     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2015-05-29 4 AS $126.15 $199,065 D/D (1,578) 35,624     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2015-05-29 4 D $125.57 $540,579 D/D (4,305) 37,202     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2015-05-26 4 AS $126.55 $205,647 D/D (1,625) 39,245     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-05-21 4 S $126.10 $189,157 I/I (1,500) 31,758     -
  1285 Records found
  Previous  40  41  42  43  44  45  46  47  48  49  Next   
  Page 46 of 52
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us